Photo of Michael C. Heinrich, M.D.

Michael C. Heinrich M.D.

    • Professor of Medicine School of Medicine
    • Cell and Developmental Biology Graduate Program School of Medicine
    • Cancer Biology Graduate Program School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

Dr. Heinrich's research includes both preclinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic. This includes both genomics research using high-throughput gentoyping to identify oncogenic mutations and testing of new compounds in cellular and biochemical assays. Dr. Heinrich’s laboratory is particularly expert in the analysis of inhibitors of oncogenic receptor tyrosine kinases such as KIT, PDGFRA and FLT3.


  • M.D., Johns Hopkins University School of Medicine, 0 1984
  • Residency:

    • Oregon Health & Science University, 1988
  • Fellowship:

    • Hematology/medical oncology, Oregon Health & Science University, 1991
  • Certifications:

    • American Board of Internal Medicine, (internal medicine) 1987

Memberships and associations

  • American Society of Clinical Oncology


  • "Translational insights into gastrointestinal stromal tumor and current clinical advances." Annals of oncology : official journal of the European Society for Medical Oncology  In: , Vol. 29, No. 10, 01.10.2018, p. 2037-2045.
  • "Integrated molecular characterization of gastrointestinal stromal tumors (GIST) harboring the rare D842V mutation in PDGFRA gene." International Journal of Molecular Sciences  In: , Vol. 19, No. 3, 732, 04.03.2018.
  • "Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases." Pharmacology and Therapeutics  In: , 01.01.2018.
  • "LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma." Oncogene  In: , 01.01.2018.
  • "Gastrointestinal stromal tumours of the oesophagus : a clinicopathological and molecular analysis of 27 cases." Histopathology  In: , Vol. 71, No. 5, 01.11.2017, p. 805-812.
  • "Biochemical, molecular, and clinical characterization of succinate dehydrogenase subunit A variants of unknown significance." Clinical Cancer Research  In: , Vol. 23, No. 21, 01.11.2017, p. 6733-6743.
  • "A precision therapy against cancers driven by KIT/PDGFRA mutations." Science Translational Medicine  In: , Vol. 9, No. 414, eaao1690, 01.11.2017.
  • "Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results : Analysis of Phase 3 SWOG Intergroup Trial S0033." JAMA oncology  In: , Vol. 3, No. 7, 01.07.2017, p. 944-952.
  • "Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors." Expert Review of Molecular Diagnostics  In: , Vol. 17, No. 5, 04.05.2017, p. 445-457.
  • "MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation." Nature Communications  In: , Vol. 8, 14674, 08.03.2017.
  • "PDGFRA Antibody for Soft Tissue Sarcoma." Cell  In: , Vol. 168, No. 4, 09.02.2017, p. 555.
  • "CKIT."   Cancer Therapeutic Targets. Vol. 2-2 Springer New York, 2017. p. 683-692.
  • "Defining the impact of adjuvant therapy in molecularly defined subsets of gastrointestinal stromal tumor : From lumping to splitting." JAMA oncology  In: , Vol. 3, No. 5, 2017, p. 597-599.
  • "FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors." Journal of Translational Medicine  In: , Vol. 14, No. 1, 339, 14.12.2016.
  • "Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy." Annals of Oncology  In: , Vol. 27, No. 9, mdw228, 01.09.2016, p. 1794-1799.
  • "Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib." Oncotarget  In: , Vol. 7, No. 27, 05.07.2016, p. 41390-41403.
  • "Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour." European Journal of Cancer  In: , Vol. 61, 01.07.2016, p. 94-101.
  • "Regorafenib for treatment of imatinib- and sunitinib-resistant metastatic gastrointestinal stromal tumors." Expert Opinion on Orphan Drugs  In: , 09.05.2016, p. 1-12.
  • "Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial." BMC Cancer  In: , Vol. 16, No. 1, 22, 15.01.2016.
  • "S0502 : A SWOG phase III randomized study of imatinib, with or without bevacizumab, in patients with untreated metastatic or unresectable gastrointestinal stromal tumors." Oncologist  In: , Vol. 20, No. 12, 17.11.2015, p. 1353-1354.
  • "SDHC methylation in gastrointestinal stromal tumors (GIST) : A case report." BMC Medical Genetics  In: , Vol. 16, No. 1, 87, 28.09.2015.
  • "Genotyping and immunohistochemistry of gastrointestinal stromal tumors : An update." Seminars in Diagnostic Pathology  In: , Vol. 32, No. 5, 01.09.2015, p. 392-399.
  • "KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors : Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation." Journal of Clinical Oncology  In: , Vol. 33, No. 22, 01.08.2015, p. e93-e96.
  • "Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition." Clinical Cancer Research  In: , Vol. 21, No. 10, 15.05.2015, p. 2289-2296.
  • "Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance." Cancer Research  In: , Vol. 75, No. 5, 01.03.2015, p. 880-891.
  • "Quadruple wild-type (WT) GIST : Defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways." Cancer Medicine  In: , Vol. 4, No. 1, 01.01.2015, p. 101-103.
  • "Combination therapy for KIT-mutant mast cells : Targeting constitutive NFAT and KIT activity." Molecular Cancer Therapeutics  In: , Vol. 13, No. 12, 01.12.2014, p. 2840-2851.
  • "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients." Clinical Cancer Research  In: , Vol. 20, No. 22, 15.11.2014, p. 5745-5755.
  • "Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)." BMC Cancer  In: , Vol. 14, No. 1, 685, 20.09.2014.
  • "Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor : The ACOSOG Z9001 trial." Journal of Clinical Oncology  In: , Vol. 32, No. 15, 20.05.2014, p. 1563-1570.

Additional information

Edit profile